Monoclonal gammopathy of undetermined significance other imaging findings
|
Monoclonal gammopathy of undetermined significance Microchapters |
|
Differentiating Monoclonal gammopathy of undetermined significance from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Monoclonal gammopathy of undetermined significance other imaging findings On the Web |
|
American Roentgen Ray Society Images of Monoclonal gammopathy of undetermined significance other imaging findings |
|
FDA on Monoclonal gammopathy of undetermined significance other imaging findings |
|
on Monoclonal gammopathy of undetermined significance other imaging findings |
|
Monoclonal gammopathy of undetermined significance other imaging findings in the news |
|
Blogs on Monoclonal gammopathy of undetermined significance other imaging findings |
|
Directions to Hospitals Treating Monoclonal gammopathy of undetermined significance |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2]
Overview
99mTc-Sestamibi and PET/CT may be helpful in the diagnosis of MGUS. 99mTc-Sestamibi show increased mitochondrial activity and findings on PET/CT may show early involvement of bone marrow.
Other Imaging Findings
99mTc-Sestamibi and PET/CT may be helpful in the diagnosis of MGUS. 99mTc-Sestamibi show incresaed mitochondial activity and findings on PET/CT may show early involvement of bone marrow.[1] PET/CT is also commonly performed to assess for osseous lesions, as PET/CT is very sensitive for bone breakdown.
References
- ↑ Mena E, Choyke P, Tan E, Landgren O, Kurdziel K (January 2011). "Molecular imaging in myeloma precursor disease". Semin. Hematol. 48 (1): 22–31. doi:10.1053/j.seminhematol.2010.11.006. PMC 3023940. PMID 21232655.